Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge

Authors

  • Nathalie Etchart,

    1. Lung Immunology group, The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, UK
    2. Inserm U404 “Immunité et Vaccination“, IFR 74 – CERVI, 21 Avenue Tony Garnier, F-69365 Lyon cedex 07, France
    Search for more papers by this author
  • Bas Baaten,

    1. Lung Immunology group, The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, UK
    Search for more papers by this author
  • Svein Rune Andersen,

    1. Carbohydrate Immunology group, The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, UK
    2. Norwegian Medicines Agency, Sven Oftedals vei 6, N-0950 Oslo, Norway
    Search for more papers by this author
  • Lisa Hyland,

    1. Lung Immunology group, The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, UK
    Search for more papers by this author
  • Simon Y. C. Wong,

    1. Carbohydrate Immunology group, The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, UK
    Search for more papers by this author
  • Sam Hou Dr.

    Corresponding author
    1. Lung Immunology group, The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire, UK
    • The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire RG20 7NN, UK, Fax: +44-1635-577901
    Search for more papers by this author

Abstract

We have previously shown that following intranasal exposure to influenza virus, specific plasma cells are generated in the nasal-associated lymphoid tissue (NALT) and maintained for the life of the animal. However, we also showed that following infection with respiratory syncytial virus (RSV), specific plasma cells are generated in the NALT but wane quickly and are not maintained even after challenge, even though RSV-specific serum antibody responses remain robust. Only infection with influenza virus generated sterilising immunity, implying a role for these long-lived plasma cells in protection. We show here that the RSV-specific IgA NALT plasma cell population and lung antibody levels can be substantially boosted, both at acute and memory time points, by intranasal immunisation with inactivated RSV (iRSV) in combination with bacterial outer membrane vesicles (OMV) compared to live RSV alone. Finally, challenge with live RSV showed that immunisation with iRSV and OMV protect against both virus replication in the lung and the eosinophil infiltrate generated by either live RSV or iRSV alone. These data show that immunisation with iRSV and OMV maintains a NALT RSV-specific plasma cell population and generates an efficient protective immune response following RSV infection.

See accompanying commentary: http://dx.doi.org/10.1002/eji.200636118

Ancillary